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Background: Psoriasis is an immune-mediated disease characterised by chronically elevated pro-inflammatory
cytokine levels, leading to aberrant keratinocyte proliferation and differentiation. Although certain clinical
phenotypes, such as plaque psoriasis, are well defined, it is currently unclear whether there are molecular subtypes
that might impact on prognosis or treatment outcomes.
Results: We present a pipeline for patient stratification through a comprehensive analysis of gene expression in
paired lesional and non-lesional psoriatic tissue samples, compared with controls, to establish differences in RNA
expression patterns across all tissue types. Ensembles of decision tree predictors were employed to cluster psoriatic
samples on the basis of gene expression patterns and reveal gene expression signatures that best discriminate
molecular disease subtypes. This multi-stage procedure was applied to several published psoriasis studies and a
comparison of gene expression patterns across datasets was performed.
Conclusion: Overall, classification of psoriasis gene expression patterns revealed distinct molecular sub-groups
within the clinical phenotype of plaque psoriasis. Enrichment for TGFb and ErbB signaling pathways, noted in one
of the two psoriasis subgroups, suggested that this group may be more amenable to therapies targeting these
pathways. Our study highlights the potential biological relevance of using ensemble decision tree predictors to
determine molecular disease subtypes, in what may initially appear to be a homogenous clinical group. The R code
used in this paper is available upon request.
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Psoriasis is one of the most prevalent chronic inflamma-
tory disorders caused by an interplay of genetic factors
and the environment on the background of dysregula-
ted immune system [1]. The disease affects 2 - 3% of the
population worldwide [2] and can be variable in morph-
ology, severity and distribution. There are several clinical
variants of psoriasis, but the most common variant,
plaque psoriasis, is characterised by chronic, symmetrical,
silvery-scaled, sharply circumscribed plaques [1,3]. Plaque
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reproduction in any medium, provided the orcan begin in childhood and late adolescence (Type 1) or
in adulthood (Type 2), with a predilection for elbows,
knees and the scalp.
Although the cause of psoriasis remains unknown, it is
thought to be a complex and multifactorial disorder
brought about by the combination of multiple suscepti-
bility genes [4-6], a dysregulated immune system [7,8]
and environmental factors [9]. Through Genome Wide
Association Studies (GWAS) [10,11], a number of gen-
etic variants have been identified as contributing
towards psoriasis pathogenesis. A unifying model that
integrates genetic, environmental and immunological
aspects of skin inflammation has been proposed [12].
In recent years, progress has been made in under-
standing the pathogenesis and treatment of psoriasis.
Pathogenesis is mainly linked to activation of several
types of leukocytes that control cellular immunity and to
a T-cell-dependent inflammatory process in skin thattd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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psoriasis lesions. Current therapeutic approaches against
the disease take advantage of proteins or antibodies aim-
ing either at specific inflammatory co-activators or more
generally at immune cells [3]. While there is now
increasing insight into the genes conferring disease sus-
ceptibility, much less is known about the types of regula-
tory networks of expressed genes which define the
molecular signature of the disease.
The first large-scale and detailed gene expression stud-
ies of psoriasis identified various differentially expressed
genes by comparing non-lesional and lesional skin
against normal tissue [13-16]. Recent studies have
attempted to elucidate the molecular pathways under-
lying in psoriasis [17-20]. However, determining genes
that contribute to complex human disorders through
analysis of microarray data is challenging due to the
large number of gene predictors, their possible interac-
tions, and the small number of samples. Termed the
“small n, large p” problem [21], this implies that classical
statistical methods cannot be implemented directly in
functional genomics approaches for the identification of
diagnostic or prognostic biomarkers. In this respect, de-
cision trees have proven to be a sensible non-parametric
method for classification and variable selection [22].
Random forest (RF) classification is an ensemble of
CART decision trees and has been found to outperform
other machine learning techniques for analysis of micro-
array data [23-26].
In this study, a computational methodology based on
decision tree predictors is developed to discover molecu-
lar sub-groups from gene expression data and illustrate
gene signatures associated with each group. The random
forest (RF) algorithm [22] is used here to (i) cluster psor-
iasis transcripts into subgroups and (ii) discriminate
between disease phenotypes and generate gene signa-
tures that best differentiate them. RF has been shown to
be robust in noisy data, to avoid over-fitting in cases
where the number of features is larger than the number
of observations and to be particularly suitable for the
feature selection process [24,27,28].
More specific to the current analysis, we first analysed
gene expression profiles in normal and disease skin tis-
sues, so as to define common differentially expressed
genes. This core gene set was then used to group psori-
atic tissue samples through RF clustering of real and
synthetic data, as previously developed [29]. This step
resulted in dividing psoriatic tissues into two subgroups
according to similarity of gene expression patterns.
Finally, RF classification was used to derive gene signa-
tures able to discriminate between normal and disease
phenotypes, including the above-proposed new psoriatic
subgroups. Such gene signatures are discussed in follow-
ing sections with respect to their effect on definingdistinct molecular characteristics and were validated
through comparisons with other psoriasis gene expres-
sion studies.
Molecular profiling of psoriatic phenotypes followed
by classification of tissue samples into appropriate dis-
ease classes has the potential to derive clusters of similar
transcription responses from the entire repertoire of
profiles generated. Especially in the case of a homoge-
neous clinical patient group, such as plaque-type psoria-
sis, the classification of transcriptional patterns into
appropriate sub-groups may reveal distinct molecular
mechanisms that may operate within this group and
may explain variability in response and options of dis-
ease treatment. Overall, given the predictive nature of
the decision model employed, such patient categorisa-
tions can lead to significant insights into disease
mechanisms and novel, targeted therapeutic approaches.
Results and Discussion
A pipeline (Figure 1) for patient stratification according
to gene expression profiles in psoriasis was implemented
to generate molecular sub-groups and uncover gene sig-
natures associated with each disease group. Such an ap-
proach has possible predictive implications: given
relevant expression measurements for key signature
genes, uncharacterised tissue samples can be ascribed to
these predefined disease classes, which can reflect differ-
ent disease prognosis or response to treatment.
Gene expression patterns define a core set of
dysregulated genes among normal, non-lesional and
lesional skin
Skin samples from psoriatic patients were either of
inflamed, lesional type (PP, involved skin) or non-
inflamed, non-lesional tissue (PN, uninvolved skin).
These were analysed together with skin samples from
normal individuals (denoted as NN). Relevant gene ex-
pression measurements for the disease classes (NN, PN
and PP) were obtained through the Genetic Association
Information Network (GAIN, see Methods). Differential
expression analysis was performed and involved three
pairwise comparisons between tissue datasets (i.e. NN
vs. PN, PN vs. PP and NN vs. PP), resulting in three sets
of differentially expressed probe sets per pair (p-value
< 0.05 and FDR < 0.05). A set of 228 probes was shared
across all datasets (Figures 1 and 2a) and corresponded
to a total number of 206 unique genes, of which 130
genes were over-expressed and 76 under-expressed in
PP samples compared to NN (Additional file 1: Table S1).
This group of genes constituted a core set of genes ex-
pressed differentially across the three disease phenotypes
and was used to derive disease-specific expression pat-
terns in the RF-based procedure described in the following
sections.
Figure 1 Pipeline for patient stratification. For further details on related methodology, please see main text.
Ainali et al. BMC Genomics 2012, 13:472 Page 3 of 15
http://www.biomedcentral.com/1471-2164/13/472Unsupervised hierarchical clustering was carried out
on the set of 206 core genes to explore and visualise the
patterns of gene expression from normal (NN) to non-
lesional (PN) and then to lesional (PP) skin samples.
Figure 2b shows an overview of gene expression for the
core probe sets, clustered according to similarity of ex-
pression across NN, PN and PP samples. This visualisa-
tion represents a striking outline of the varying
transcriptional patterns at each disease phase, progres-
sing gradually from generally non-differentiated gene ex-
pression in non-inflamed tissues (NN, PN), to markedly
differentiated genes in lesional samples (PP).
Principal component analysis (PCA) was used to assess
the clustering of samples when progressing from un-
inflamed to inflamed skin. There was a clear distinction
between lesional (PP) and non-lesional (NN and PN)
phenotypes (Figure 2c), manifested as distinct clusters ofsamples from normal to the involved phenotype through
non-involved skin. Normal and psoriatic un-involved
samples (NN and PN) co-clustered away from involved
cases (PP), in agreement with previously published ana-
lyses [16,19]. This demonstrated the changes in gene ex-
pression profiles across NN, PN and PP skin and
revealed a marked difference between inflamed (PP) skin
and un-inflamed (PN and NN) phenotypes.
Among the strongly dysregulated genes in the core gene
set (Additional file 1: Table S1), several of the under-
expressed genes were found to encode proteins involved
in fibrotic processes and immune responses. For example,
FN1, PDGFC, MYH10 are involved in the regulation of
the actin cytoskeleton, which participates in fundamental
processes such as the regulation of cell shape, motility and
adhesion [30]. DIXDC1, CGNL1 and SSPN encode cell ad-
hesion and junction proteins. Betacellulin (BTC), IL1F7,
Figure 2 Differential gene expression in lesional (PP), non-lesional (PN) and normal (NN) skin tissue. Gene expression was analysed to
reveal probe sets that were differentially expressed between pairwise comparisons of PP, PN and NN tissue groups. (A) The Venn diagram shows
the number of probe sets identified in each of the three differential analyses performed. Probe sets common to all three pairwise comparisons
were 228 (206 genes). (B) Microarray analysis of 108 skin tissue samples (in columns) for 206 genes (in rows) common to all tissue types,
identified through differential expression analysis. Tissues have been grouped according to disease phenotype (normal NN, non-lesional PN and
lesional PP) and heatmap colours indicate z-score of each gene expression value against the mean of corresponding normal values, (green:
decreased expression, red: increased expression, inset). Similarity of gene expression vectors across all samples is represented by the dendrogram
on the left. (C) Principal Component Analysis to suggest sample clustering across skin types according to gene expression patterns. Good
separation of inflamed (PP) and non-inflamed (PN, NN) tissues was observed, indicating a progression from normal (red) to lesional skin (blue)
through the non-lesional cases (green).
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genes. In addition, MEGF9, BTC, FN1, PHF2 belong to
the family of growth factors that activate the epidermal
growth factor receptor, EGFR (ErbB1) and according to a
previous study BTC plays an important role in skin mor-
phogenesis [31]. Among the over-expressed genes, several
participate in keratinocyte proliferation and differentiation
(EREG, KLK8 and PPARD). Of note is KLK8, potentially
involved in the modulation of hyperkeratosis in a psoriatic
lesion and may be implicated in preventing excessive kera-
tinocyte proliferation, resulting in increased shedding of
corneocytes. This is clinically reflected in the copiousquantities of scale that are shed by psoriasis patients [32].
Genes LTB4R2 and PPARD are also involved in keratino-
cyte migration. Finally, a group of up-regulated genes
SNRPG, SNRPD1, SNRPD3, SNRPA1, SNRPC, SF3B14,
SFRS9 is involved in spliceosomal assembly. Overall, most
dys-regulated genes were found to be consistent with
current knowledge.
Distinctive gene expression patterns between lesional
and non-lesional tissues (PP vs. PN)
Following the general patterns of psoriatic tissue differen-
tiation, the use of decision tree ensembles was explored to
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major gene patterns able to discriminate the psoriatic phe-
notypes (see Figure 1, step1). We used 74 tissue samples
from psoriasis patients, each characterised by a vector of
core gene expression values, and a random forest (RF)
classifier [22] was applied to distinguish samples in
lesional (PP) and non-lesional (PN) phenotypes. The clas-
sifier employed 1000 trees with training of each tree per-
formed on 2/3 of samples and testing on the remaining 1/3
(see Methods and Additional file 2: Supplementary Meth-
ods). The prediction accuracy of the classifier was high (ac-
curacy 97.3%, OOB error rate 2.7%).
The random forest classifier was then used to indicate
the relevant importance of features in the classification,
i.e. which genes are more important in predicting the
appropriate disease class. Genes were ranked through
the Gini Index (GI) in terms of their discriminative
power (see Methods) and Figure 3 shows genes with the
highest GI when distinguishing inflamed (PP) from non-
inflamed (PN) skin. Five genes indicated through this
procedure were IL1F7, C7orf59, AQP9, BTC and TUFT1
and were all related to immune response processes.
Identification of molecular sub-types within psoriatic
tissue samples
In addition to key patterns that defined disease outcome
in psoriatic tissues above, we used random forest inFigure 3 Informative genes for the classification of skin samples in le
Index (GI) was used to generate a variable importance measure and provid
most important genes in determining disease classes were IL1F7, C7orf59, Aunsupervised mode, as a clustering platform to group
lesional psoriasis samples based on their gene expression
properties (see Figure 1, step 2). The aim was to generate
two sub-groups among disease tissues (PP), before fur-
ther classification runs could identify molecular differ-
ences among them (Figure 1, step 3, discussed later). As
described previously [29], first synthetic data were gener-
ated by randomly sampling the gene expression observa-
tions. Then, a random forest predictor was built to
distinguish the real from synthetic data (see Methods)
and define a similarity measure between the psoriatic
cases in the form of the random forest proximity meas-
ure. Finally, CLARA clustering of the proximity matrix
partitioned the psoriatic cases into two groups, named
PP01 and PP02 (Figure 1, step 2). The adjusted rand
index to indicate the difference between the two identi-
fied sub-groups was -0.0269.
The RF-derived proximity measure can be used to
generate a multi-dimensional scaling (MDS) plot, where
dissimilarities between samples return a set of points in
low dimensional Euclidian space, similar to principal
component analysis. The MDS plot projects data into a
2D space giving the similarities among patients and their
respective classes. The distinction of samples in two
groups, PP01 (red circles) and PP02 (black circles) is shown
through the MDS plot in Additional file 3: Figure S1.
Similar clustering of PP phenotypes in two clusters hassional and non-lesional classes (PP and PN, respectively). Gini
e an estimate of feature (gene) relevance to disease state. The five
QP9, BTC and TUFT1.
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shown) and was used as means of determining the
optimum number of psoriatic sub-groups.
The relationship between these sub-groups and clinic-
ally measurable parameters, was assessed. Psoriasis Area
and Severity Index (PASI), Body Mass index (BMI), Age
of Onset, Age and Body Surface Area (BSA) were evalu-
ated against subgroups PP01 and PP02. Of these, age
was found to be significantly altered between the two
subgroups (p-value 0.0184, Wilcoxon signed-rank test).
It is emphasised here that plaque-type psoriasis constitu-
tes a homogeneous clinical group, distinct from other
forms of psoriasis. Therefore, it is not surprising that
such coarse-grained clinical parameters can not capture
the subtle differences in plaque psoriasis sub-groups
(PP01, PP02). Instead, our focus here is to distinguish
the underlying biological mechanisms, in terms of dis-
tinct biochemical pathways and interactions that act in
these subgroups, as we report in following sections.
Having separated psoriatic samples in two sub-groups,
a new gene expression matrix, where PP samples were
split in PP01 and PP02, was used as input to another
round of RF classification (see Figure 1, step 3). The core
genes (total of 206) were used as variables to classify 108
samples in any of the four classes (normal NN, non-
lesional PN, first lesional group PP01, or second lesional
group PP02). The purpose of this series of experiments
was to assess the discriminatory power of different genes
in deriving the four disease classes through classification.
The classifier showed good prediction accuracy (79.6%,
OOB error rate 20.37%, 1000 trees). Figure 4 shows the
MDS plot for this classification experiment, illustrating
the relative clustering of samples in four skin pheno-
types. As before, non-inflamed tissues (NN and PN)
clustered away from the inflamed tissues (PP). Addition-
ally, the relative segregation of the two PP subgroups
was also apparent.
The contribution of particular genes in differentiating
the corresponding disease phenotypes was also assessed
through Gini Index as variable importance measure and
Figure 5 illustrates a measure of the discriminative
power of genes in classification. Functional information
of the five top-scoring genes is listed in Table 1, in terms
of chromosomal location, GO class and pathway partici-
pation. This set of most informative genes in Figure 5
and Table 1 was also confirmed by calculating the em-
pirical p-value by permutating the tissue labels [33] (see
Methods).
To extract the differences in gene expression between
the two psoriasis sub-groups, we generated a co-
expression network of the core genes for each of these
groups (Additional file 4: Figure S2, see also Methods).
This resulted in two networks for PP01 and PP02 with dif-
ferent topological properties. The PP01 network consistedof 122 nodes with 142 edges, whilst PP02 had 173 nodes
with 472 edges. After clustering with MCL [34], 36 clus-
ters were identified for each patient group, PP01 and
PP02, and functional enrichment analysis of the largest
clusters has indicated different biochemical pathways
linked to each of these groups. The PP01 network clusters
were enriched in signaling pathways, such as Wnt,
Notch, TGF-beta, ErbB signaling pathways, whereas
clusters in PP02 network were more involved in meta-
bolic pathways (Tables 2 and 3). This indicated that
the two lesional psoriatic sub-groups possess different
functional properties, suggesting different underlying
biological processes.
Identification of key genes associated with disease sub-
classes and comparison with other studies
Variable importance analysis was used to derive highly
discriminative genes in classification of disease sub-
types. As described previously (see Methods), the Gini
Index (GI), calculated from RF classification (108 sam-
ples, 206 genes, 4 classes, see Figure 1, Step 3), was used
to rank each of the 206 genes in terms of their discrim-
inatory effect in assigning samples in each of the four
tissue groups (NN, PN, PP01, PP02). The 43 genes with
highest GI were schematically represented in a circular
layout (Figure 6) to show their effect in each of the four
classes. For example, BTC, part of the ErbB and ERK
Signaling pathways, has GI equal to 0.11 for samples
classified in the PP01 class and a significantly lower GI
when classifying samples in the other tissue groups
(GI = 0.041 for NN, GI = 0.056 for PN and GI = 0.055
for PP02). Similarly, the importance of the other 43
genes in classifying samples in the four phenotype
classes was determined and is illustrated (Figure 6).
In the NN group, CNFN and BUB3 were more fre-
quently selected to define a split in the classification
trees of the forest, whereas BTC, IL1F7 and TMEM99
(GI > 0.02) were important in classification of PN sam-
ples. Within the PP group, BTC, C20orf11, EEF1A1,
CNFN, IL1F7, PRSS1/TRY6, SSPN and UCHL3 showed
high discriminative value for identifying the PP01 sub-
group, whereas BTC, CNFN, IL1F7, KLK8/KLK9 and
TXNDC4 exhibited high importance for the PP02 sub-
group (Additional file 5: Figure S3). To further support
linking these genes to psoriasis-related biological
mechanisms, the PubMatrix tool was used to look up
the discriminatory genes in the context of eight terms,
including”psoriasis”, “NK cells”, “T cells”, “immune re-
sponse”, “Wnt signaling pathway”, “Notch signaling
pathway”, “TGF – beta signaling pathway” and “ErbB
signaling pathway” [35]. Out of 43 genes, 24 genes were
found to occur together with these terms in biomedical
literature, as seen in Figure 7 (see also Additional file 6:
Table S2). Interestingly, BTC, which exhibited a high
Figure 4 A multidimensional scaling (MDS) plot to illustrate the molecular grouping of samples. A dissimilarity matrix in random forest is
constructed through the use of synthetic data drawn from the distribution of psoriatic samples (see Methods). Patients are clustered according to
these dissimilarities and two distinct psoriatic groups are identified, PP01 (green) and PP02 (purple). All lesional samples (PP) cluster away from
both normal (NN) and non-lesional (PN) tissue samples, in accordance to observations in figure 2c.
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was found to be related with the ErbB signaling pathway.
The latter was a highly enriched pathway in this sub-
group and indicates a potential therapeutic target.
IL1RN also had a high GI for samples classified as PP01
and was previously found to be highly related with T cell
activation and immune response.
The pipeline outlined above was replicated with two
other psoriatic datasets from [18] (Gudjonsson dataset)
and [36] (Yao dataset). Skin samples were grouped into
sub-types according to their gene expression patterns as
for the GAIN dataset, using similarities derived from the
proximity matrix through random forest (an MDS plot
for Gudjonsson and Yao data is shown in Additional file
7: Figure S4). The circular representation of the most im-
portant genes was also followed here and the 19 most in-
formative genes from Gudjonsson and 27 from Yao
datasets are shown (Additional file 8: Figure S5 and
Additional file 9: Figure S6). By comparing across the three
datasets and the relevant gene signatures, the importance
of specific genes was noted. BTC, CNFN, IL1F7 were
important discriminant genes in the GAIN data, while
SNRPC and SMURF2 played a greater role in the Yao and
Gudjonsson datasets. Generating a consistent outcome of
gene signatures across all datasets is challenging, as patientcohorts may vary significantly. Although the Yao data seem
difficult to reproduce, considerable similarity exists between
the other two datasets. Specifically, one of the disease sub-
groups in these dataset points to pathways related to
NOTCH signaling, ErbB and TGF beta suggesting that
this group may be more amenable to related thera-
peutic options (see Tables 2, 3, Additional file 10:
Table S3 and Additional file 11: Table S4).
We note that evaluation of psoriasis transcriptomes
has been assessed elsewhere [20] and the observed
low reproducibility across various studies was attrib-
uted to wide variability in clinical protocols, plat-
forms and sample handling among different datasets.
It is envisaged that the application of the present
and similar strategies for predictive modelling and
stratification of expression patterns, as well as the
availability of larger patient studies will bridge the
disparities between various studies and yield a
sharper picture of gene contributions to this com-
plex disorder.
Conclusions
Large-scale genome characterisations, through the ana-
lysis of gene sequence and expression data, are gaining
increasing interest and have the potential to greatly
Figure 5 Genes identified as most informative through RF classification of skin tissues in four molecular groups (NN, PN, PP01 and
PP02). Gini Index (GI) was used as variable importance measure for estimating the discriminative power of relevant features (genes) and,
consequently, their relevance to disease state. The five most important genes in determining disease classes were BTC, CNFN, C20orf11, BUB3 and
IL1F7. Genes with related annotation are listed in Table 1.
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lecular mechanisms underlying disease pathogenesis and
progression. Various models of data stratification and
identification of patient groups through various data
mining protocols are used to support a decision making
process in biomedicine. Data mining procedures based
on algorithms such as support vector machines (SVM),
neural networks, decision tree algorithms and mathem-
atical programming approaches have been used to select
sets of genes for diagnostic purposes and to identify mo-
lecular roles which are - as yet- unknown [37]. Here we
have illustrated the use of random forest to partition
psoriatic tissues in appropriate disease groups and gen-
erate estimates of relevant gene predictors.
Psoriasis is a common, complex immuno-genetic in-
flammatory disease of primarily the skin. The underlying
genetics of the disease are complex with numerous impli-
cated susceptibility genes, where replication of single loci
has been confirmed for only a handful of these genes.
Patients suffering from psoriasis can exhibit a host of dif-
ferent clinical phenotypes and response to therapy is var-
ied and unpredictable, even within a similar clinical
phenotype, suggesting underlying transcriptional differ-
ences between and within the clinical groups. The ability
to investigate the underlying immuno-genomic compo-
nents of these clinical sub-phenotypes has not been apossibility, until now. Identification of different transcrip-
tional signatures and their associated molecular pathways
contribute toward defining a set of biomarkers, which
could serve as diagnostic and therapeutic responder
tools. We have outlined a computational strategy to iden-
tify molecular sub-types and corresponding putative bio-
markers that may be crucial in the understanding and
prediction of disease pathogenesis. Of the 206 common
differentially expressed genes identified between normal,
psoriatic lesional and psoriatic non-lesional groups, 130
genes (63.1%) were up-regulated and 76 genes (36.9%)
were down-regulated. Dysregulated genes discovered in
this study were involved in epidermal cell modulation,
cell cycling and immune responses.
Microarray analysis of gene expression has been widely
used to differentiate lesional and non-lesional skin of psori-
atic patients [38,39]. Recently, large-scale analysis using
whole genome array platforms on numerous patients per
sample group have been undertaken with the aim of identi-
fying gene expression profiles associated with a specific
psoriatic phenotype [5,6,10,40]. In this work, we present a
method for identifying sub-phenotypes of lesional skin from
psoriasis patients based on patterns of gene expression that
characterise each group and differ significantly from normal
human skin. This approach is based on a decision tree ana-
lysis of gene expression data, the extraction of associations
Table 1 Functional annotation for most informative genes
BTC Description: betacellulin
Chromosomal region: chr4q13-q21
GO-BP: cell proliferation, positive regulation of cell proliferation
GO-MF: epidermal growth factor receptor binding, growth factor activity, growth factor activity
GO-CC: extracellular region, soluble fraction, plasma membrane, integral to membrane
Pathway: ErbB signalling, ERK signaling
CNFN Description: cornifelin
Chromosomal region: chr19q13.2
GO-BP: keratinization
GO-MF: NA
GO-CC: cornified envelope, cytoplasm
Pathway: NA
C20orf11Description: Protein C20orf11 (two hybrid-associated protein 1 with RanBPM) (Twa1)
Chromosomal region: chr20q13.33
GO-BP: NA
GO-MF: protein binding
GO-CC: nucleus
Pathway: NA
BUB3 Description: budding uninhibited by benzimidazoles 3 homolog (yeast)
Chromosomal region: chr10q26
GO-BP: mitosis, cell proliferation, anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process,
negative regulation of ubiquitin-protein ligase activity during mitotic cell cycle
GO-MF: protein binding
GO-CC: kinetochore, nucleus, cytosol
Pathway: Cell cycle role of APC in cell cycle regulation
IL1F7 Description: interleukin 1 family, member 7 (zeta)
Chromosomal region: chr2q12-q14.1
GO-BP: immune response
GO-MF: cytokine activity, interleukin-1 receptor binding, interleukin-1 receptor antagonist activity
GO-CC: extracellular region
Pathway: Systemic lupus erythematosus signaling, role of cytokines in mediating communication between immune cells, graft-versus-host
disease signaling, p38 MAPK signaling, atherosclerosis signaling
Ainali et al. BMC Genomics 2012, 13:472 Page 9 of 15
http://www.biomedcentral.com/1471-2164/13/472among gene expression patterns and the identification of
functional annotations and molecular signatures.
The random forest decision tree model was applied to
lesional skin group to derive patient sub-groups (PP01
and PP02), which are characterised by specific differen-
tially expressed genes. The PP01 group was defined by the
up-regulation of HLA-E, which is the inhibitory ligand for
innate NK cells. HLA-E takes part in processing and pre-
senting antigen to innate immune cells. The PP02 group
had more up-regulated genes related to the cells of the
adaptive immune system such as CTLA-4 (associated with
modulation of T helper responses), IFI30 (involved in
MHC Class II antigen processing), IL4IL (immunomodu-
latory enzyme produced by dendritic cells), PTPN2 (asso-
ciated with autoimmune disorders such as type 1 diabetes
mellitus and Crohn’s disease) and most interestingly
SERPINB8, which has been identified through Genome-Wide Association Studies (GWAS) as a new psoriasis sus-
ceptibility locus in the Chinese population [41].
With regards to mechanistic details on the pathways
that operate in psoriatic sub-groups, the ErbB signaling
pathway has been identified for subgroup PP01 (Table 2).
This pathway consists of a family of four related recep-
tor tyrosine kinases (ErbB1-4) which, when activated
trigger many different signal transduction pathways
leading to increased proliferation, survival, motility, and
invasiveness [42]. All of these responses are important
aspects of wound healing and psoriasis has many ele-
ments in common with wound healing. The main clin-
ical feature of psoriasis relates to the thickened
epidermis as a result of what may initially have been an
epidermal barrier insult. An attempt to restore epider-
mal integrity is reflected in the activation of the ErbB
signaling pathway. However in psoriasis it is possible
Table 2 Pathway enrichment in the PP01 psoriatic group
Pathway name p-value q-value
Cluster1
NOTCH1 Intracellular Domain Regulates Transcription 0.0008 0.0227
Signaling by NOTCH1 0.0017 0.0254
Signaling by NOTCH 0.0028 0.0275
NOTCH1 Intracellular Domain Regulates Transcription 0.0007 0.0227
Cluster2
Urea cycle 0.0066 0.0187
Synthesis of very long-chain fatty acyl-CoAs 0.0104 0.0187
Fatty Acyl-CoA Biosynthesis 0.0133 0.0187
Triglyceride Biosynthesis 0.0271 0.0286
Cluster3
PI3K events in ERBB4 signaling 0.0003 0.0054
PI3K events in ERBB2 signaling 0.0004 0.0054
Signaling by ERBB4 0.0019 0.0142
Signaling by ERBB2 0.0024 0.0142
AKT phosphorylates targets in the nucleus 0.0059 0.0289
Signaling by TGF beta 0.0106 0.0400
SHC1 events in ERBB4 signaling 0.0139 0.0400
GRB2 events in ERBB2 signaling 0.0152 0.0400
Signaling by BMP 0.0159 0.0400
SHC1 events in ERBB2 signaling 0.0165 0.0400
PIP3 activates AKT signaling 0.0205 0.0434
Immune System 0.0215 0.0434
PI3K/AKT activation 0.0263 0.0447
Nuclear signaling by ERBB4 0.0273 0.0447
GAB1 signalosome 0.0283 0.0447
Interleukin-1 signaling 0.0296 0.0447
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is dysregulated [43].
Other signaling pathways seem to be in effect in psoriasis
sub-group PP02 (Table 3), for example signaling by BMP.
Bone morphogenetic proteins (BMP) are members of the
transforming growth factor-beta (TGF beta) superfamilyTable 3 Pathway enrichment in the PP02 psoriatic group
Pathway name
Cluster2
Transport of Glycerol from Adipocytes to the Liver by Aquaporins
Transport by Aquaporins
Signaling by TGF beta
Signaling by BMP
Cluster3
Respiratory electron transport
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and
The citric acid (TCA) cycle and respiratory electron transportand regulate a large variety of biological responses in differ-
ent cells and tissues. It has been reported that BMPs are
implicated in a variety of pathobiologic processes in skin,
including wound healing, psoriasis, and carcinogenesis [44].
In our analysis, when several patient clinical variables
were compared across the two classes (PP01 and PP02),
we found age to be significantly altered in these sub-
groups, indicating that this is an important factor in dis-
ease manifestations. It is worth noting that although the
differences in PP01 and PP02 groups are quite marked
on a transcriptional level, yet they are clinically difficult
to distinguish. This observation may help explain why
some patients have a different disease course to others
and why some respond better to therapy than others
within a given clinical phenotype. The ability to generate
molecular sub-types provides putative biomarkers, which
with further refinement and replication, could prove to
be useful in predicting disease severity, progression and
response to therapy in an individualised manner.
Random forest has become a popular tool for analysing
high-throughput genomic data. Due to the large number
of variables associated with characterisation of clinical
samples through gene expression measurements, reduc-
tion of dimensionality through feature selection or priori-
tisation is critical in disease property prediction. Here, we
use random forest for (i) disease classification through
gene expression patterns and analysis of variable import-
ance to generate potential disease biomarkers, and (ii)
clustering of gene expression measurements to derive dis-
ease subgroups. Despite some limitation in reproducibility
across different psoriasis datasets, we believe that through
our study there is an emerging picture of important gene
predictors in psoriasis, as well as differentiation of disease
in patient subgroups. Future work based on richer data-
sets that profile larger patient cohorts, with stringent clin-
ical phenotyping, will have the potential to draw clearer
conclusions about this complex autoimmune skin disease.
In this study, we generated biologically meaningful
phenotypic classes using a ‘core’ of the highest differentially
expressed genes and then further addressing the molecularp-value q-value
0.0018 0.0158
0.0102 0.0419
0.0149 0.0419
0.0223 0.0470
0.0012 0.0009
heat production by uncoupling proteins. 0.0018 0.0009
0.0036 0.0013
Figure 6 Graphical representation to illustrate the relation between 43 highly discriminative genes and disease sub-groups.
Contributions shown according to Gini Index, calculated from random forest classification. The four skin-types (PP01: light blue, NN: green, PP02:
blue, PN: light green) followed by relevant genes are arranged clockwise. Skin groups and genes are ordered according to shared pairing links.
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sis. This might uncover subtle differences in disease patho-
genesis allowing the emergence of new treatments for
psoriatic individuals and further facilitate the development
of personalized treatments for the disease. To the best of
our knowledge, this is the first analysis identifying substan-
tial phenotypic groups in psoriasis, based on patient gene
expression profiles and using a classification pipeline. Fur-
ther analysis and discovery of patterns and associations of
transcripts of different cell-types (such as T-cells, dendritic
cells, keratinocytes) must be done to shed light on the con-
tribution that different cell types make towards the patho-
genesis of psoriasis. We would then gain a better insight
into this unique skin disease and hopefully, resolve some of
the outstanding issues related to its pathogenesis and
treatment.
Methods
Data sources
Microarray data on psoriatic gene expression were
obtained from the Genetic Association Information Net-
work (GAIN) Database [10,45], available through the
NCBI database of Genotypes and Phenotypes (dbGaP).These experiments describe tissue samples from 71 indivi-
duals, of which 34 were healthy controls (NN) and 37
patients affected by chronic plaque psoriasis. Paired sam-
ples from lesional (PP) and non-lesional (PN) tissues were
extracted and gene expression was measured by micro-
array experiments on the Affymetrix HU133 Plus 2.0
platform. Raw data were normalized using quantile
normalization and expression estimates were computed
using the Robust Multichip Average (RMA) method [46].
Analyses performed on the above gene expression
dataset were validated through comparison with gene
expression datasets GSE14905 and GSE13355 from the
ArrayExpress database [47]. The first study consisted of
21 biopsies from healthy donors and 26 paired non-
lesional and lesional plaque type psoriatic patients [36]
and the second dataset comprised 64 normal samples
and 58 psoriatic tissues [10,18]. Both studies were con-
ducted on hgu133plus2 Affymetrix chips.
Differential expression analysis
In order to define a ‘core’ dataset of differentially
expressed genes in the psoriatic phenotypes examined,
pairwise comparisons between 34 normal (NN) and 37
Figure 7 Text mining results for validation process according to the literature. Co-occurrence of gene names with disease-related terms,
such as”psoriasis”, “NK cells”, “T cells”, “immune response”, “Wnt signaling pathway”, “Notch signalling pathway”, “TGF – beta signaling pathway”
and “ErbB signaling pathway” was searched in Pubmed abstracts through PubMatrix.
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tors were performed. The differential expression between
pairs of samples (PP vs. NN, PN vs. NN, PP vs. PN) was
assessed using GenePattern [48]. Significance scores were
assigned to each probe (p-value < 0.05), multiple hypoth-
esis testing was applied with FDR < 0.05 to reduce the
false positives and the top ranked 5000 probes were
extracted for each pair of samples. Of those, the set with
the most common expression alteration among the three
pairwise comparisons was selected. Probes that mapped
to the same gene were averaged and the average intensity
across all corresponding genes was used. A core set of
228 probes common to all three pairwise comparisons
was established. Of these, a total number of 206 unique
known genes were derived yielding 130 up-regulated and
76 down-regulated genes (Additional file 1: Table S1).
Hierarchical clustering and principal component ana-
lysis (PCA) were implemented to identify distinct patterns
of gene expression within the ‘core‘206 differentially
expressed genes. The PCA procedure was implemented as
part of the PCA package in R (www.r-project.org). Un-
supervised hierarchical clustering heat-maps were gener-
ated in R based on Euclidean distance. Z-scores were
calculated from the level of normalized expressions of 206
genes according to the mean and standard deviation of a
reference set (control samples, NN).Decision tree classification model
An ensemble of decision trees model was built according
to the random forest (RF) classifier using a deterministic
algorithm (Classification and Regression Tree Algorithm,
CART) [22]. Given a gene expression matrix, a RF classi-
fier was constructed to classify tissue samples into rele-
vant disease classes (NN, PN, PP) based on gene
expression measurements (variables). Details on the clas-
sification strategy are given in Supplementary Methods
and a small example of the classification process is
shown in Supplementary Information (Additional file 12:
Figure S7). Variable importance measures were imple-
mented through mean decrease in accuracy and the Gini
Index (GI) [24], to find the genes that best discriminate
between the different disease phenotypes. Both measures
were tested and have been found to correlate well
(Additional file 13: Figure S8). The Gini Index was
adopted to express the relative effects of gene predictors
in determining the relevant disease classes. To estimate
the empirical p-value for GI, 1000 permutations of the
tissue samples were implemented and the importance
values were recalculated for the permuted data set. The
maximum Gini Index over all the genes in every permu-
tation was recorded and thereby an empirical distribu-
tion of the maximum importance was estimated, as in
similar analyses [49,50].
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tree classification
A procedure to generate clusters of disease samples
from gene expression measurements through the use of
RF is described here. The random forest proximity
measure, defined through the number of times each tree
detects these samples in the same terminal node, is used
as a means to express the similarity between samples
from gene expression observations (Additional file 2:
Supplementary Methods). Psoriatic microarray data were
used to generate molecular sub-types. Synthetic data are
generated by randomly sampling the empirical marginal
distributions of variables. RF classification is applied to
distinguish the 37 psoriatic samples from the synthetic
data and the dissimilarity matrix is used to indicate dis-
tances between psoriatic samples, as previously [29].
Through multi-dimensional scaling, samples are repre-
sented as points before clustering through CLARA [51].
This procedure was implemented in R. Statistical signifi-
cance of disease clusters with respect to clinical variables
was done through Wilcoxon signed-rank test and the
clinical variables tested were Psoriasis Area and Severity
Index (PASI), Body Mass index (BMI), Age of Onset,
Age and Body Surface Area (BSA).Network analysis and functional enrichment
Pairwise Pearson‘s correlation coefficient is estimated for
the 206 differentially expressed genes that were common
in all tissues. A similarity matrix was calculated for each
skin sub-type and a co-expression network was visua-
lised using the Cytoscape software. Markov Cluster Al-
gorithm (MCL) was used to generate the interacting
groups (clusters) via genes sharing higher-order connect-
ivity in their local neighborhoods [34]. To assess statisti-
cally significant enriched pathways involved in the four
different skin groups, p-values were calculated using the
hypergeometric statistical test and False Discovery Rate
(FDR < 0.05) was used to correct for multiple compari-
sons. The default background distribution is considered
to be the whole genome. Pathway enrichment analysis
was performed using the ReactomePA package in Bio-
conductor [52,53].Collaborative Association Study of Psoriasis
Support for genotyping of samples was provided through
the Genetic Association Information Network (GAIN).
The dataset used for the analyses described in this manu-
script were obtained from the database of Genotypes and
Phenotypes (dbGaP) found at http://www.ncbi.nlm.nih.
gov/gap through dbGaP accession number phs000019.v1.
p1. For samples and associated phenotype data, we kindly
acknowledge the Collaborative Association Study ofPsoriasis and Profs. J.T. Elder, J. Ding, W. Swindel, G.
Abecasis, P. Stuart and R. Nair.Additional files
Additional File 1: The ‘core’ set of genes defined through
differential expression analysis: positively (130) and negatively (76)
differentially expressed genes in psoriatic samples of the GAIN
dataset.
Additional File 2: Supplementary methods.
Additional File 3: A multidimensional scaling (MDS) plot showing
the distinction of psoriatic cases into two groups, PP01 (red) and
PP02 (black), as obtained after RF clustering and classification.
Additional File 4: Markov Cluster Algorithm (MCL) applied on the
psoriatic sub-group tissue sample networks to extract clusters of
gene expression. Both networks consisted of 36 clusters and the largest
clusters (number of nodes > 8) for both networks are shown and
denoted by colour. Pathway enrichment for these clusters is shown in
tables 3 and 4 for PP01 and PP02 networks respectively.
Additional File 5: Genes identified as most informative after
classification of skin disease phenotypes. Gini Index (GI) was used as
variable importance measure and was estimated for each gene per
group from random forest classification, so as to prioritise genes in terms
of their ability to discriminate distinct molecular patterns. After training of
the random forest classifier, GI is derived for each gene across all trees
and the ranking of genes with GI > = 0.02 is shown here for each skin
group.
Additional File 6: Results of text mining.
Additional File 7: A multidimensional scaling plot of psoriasis
datasets from Gudjonnson et al. 2010 [18] (A) and Yao et al. 2008
[36] (B) to illustrate grouping of samples according to random
forest clustering. Two distinct psoriatic groups are identified in involved
tissue (PP01 green and PP02 purple), while NN and PN samples largely
co-localise. Overall, clustering is comparable to GAIN data that is shown
in figure 4.
Additional File 8: Graphical representation to illustrate the
relationship between 19 highly discriminative genes and disease
sub-groups according to Gini Index calculated from decision trees
forest in the Gudjonnson dataset. The green band represents the first
psoriatic group (PP01), light blue corresponds to the second psoriatic
sub-group (PP02), yellow corresponds to healthy individuals (NN) and
light green presents the non-lesional cases (PN) and are arranged
clockwise followed by purple to orange rectangular bands that represent
relevant genes. Genes and skin groups are ordered according to shared
pairing links, as described previously.
Additional File 9: Graphical representation to illustrate the
relationship between 27 highly discriminative genes and disease
sub-groups according to Gini Index calculated from RF for the Yao
dataset. Light blue to green rectangular bands represent the four
skin-types (PP01: light blue, PP02: blue, NN: light- green, PN: green)
and are followed by purple to orange rectangular bands
representing relevant genes (arranged clockwise). Genes and skin
groups are ordered according shared pairing links. An overview of
patterns of informative genes for prediction of each disease class can
be visualised.
Additional File 10: Pathway enrichment in the Gudjonsson dataset.
Additional File 11: Pathway enrichment in the Yao dataset.
Additional File 12: Example of a decision tree for classification of
tissue samples in appropriate disease classes. Heatmap illustrates
expression values for 25 genes across 108 tissue samples and represents
part of the heatmap shown in figure 2. A decision tree is a tree-like
structure to relate gene expression measurements to sample phenotype
class, with a view to deriving a predictive model. Nodes (rectangles) in
the tree represent a test on gene expressions to derive a decision on a
sample’s class, edges (arrows) indicate the expression level of the variable
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http://www.biomedcentral.com/1471-2164/13/472that can best distinguish the samples and leaves (or terminal nodes -
circles) represent class predictions. The path from root to each terminal
node equates to a list of conditions in the form of gene expression rules
that can relate tissue samples to disease phenotype class.
Additional File 13: Correlation between the two variable
importance measures of gene selection, Gini Index and mean
decrease in accuracy.
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